AVDL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Avadel Pharmaceuticals PLC (AVDL) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company's revenue growth is impressive, the recent acquisition by Alkermes introduces uncertainties, and the lack of significant trading signals or strong positive catalysts suggests holding off on immediate investment.
The technical indicators are mixed. While moving averages are bullish (SMA_5 > SMA_20 > SMA_200), the MACD is below 0 and negatively contracting, and the RSI is neutral at 63.132. The stock is trading near its pivot point of 21.633, with no clear breakout signal.
The company's revenue increased by 54.86% YoY in Q3 2025, and Alkermes' acquisition adds FDA-approved LUMRYZ® to its portfolio, potentially enhancing competitiveness in the sleep medicine market.
Net income and EPS have dropped significantly (-100.76% and -100.00% YoY, respectively). The acquisition by Alkermes introduces integration risks and uncertainties. Analysts maintain an Equal Weight rating, indicating limited upside potential.
In Q3 2025, revenue grew by 54.86% YoY to $77.47 million, but net income dropped to $20,000 (-100.76% YoY), and EPS fell to 0 (-100.00% YoY). Gross margin improved to 93.05%, up 6.10% YoY.
Wells Fargo raised the price target to $22.50 from $20 but maintained an Equal Weight rating, reflecting a cautious outlook on the stock's potential.
